We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.92%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$515M
AUM Growth
–
Cap. Flow
+$483M
Cap. Flow %
93.73%
Top 10 Hldgs %
87.64%
Holding
24
New
22
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$104M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$76M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$65.1M
4
ARRY
Array Biopharma Inc
ARRY
+$59.9M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$44.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 70.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.94B
$136M 26.3%
+5,805,529
New +$104M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$71.1M 13.79%
+5,026,766
New +$65.1M
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$614M
$52.3M 10.14%
+6,271,558
New +$76M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$50.5M 9.81%
+11,131,858
New +$59.9M
RIGL icon
5
Rigel Pharmaceuticals
RIGL
$704M
$32.5M 6.31%
+973,070
New +$44.1M
GYRE icon
6
Gyre Therapeutics
GYRE
$648M
$26.4M 5.11%
+7,837
New +$29.8M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
$19.9M 3.86%
+1,718,905
New +$13.5M
CASC
8
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.6M 2.45%
+1,348,880
New +$17.3M
EXEL icon
9
Exelixis
EXEL
$14.1B
$11.4M 2.2%
+2,502,256
New +$11.9M
QLTI
10
DELISTED
QLT Inc
QLTI
$10.4M 2.02%
+2,370,263
New +$19.1M
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$7.51M 1.46%
+305,786
New +$6.08M
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$6.37M 1.24%
+320,000
New +$5.4M
ARQL
13
DELISTED
Arqule Inc
ARQL
$6.11M 1.19%
+2,632,432
New +$7.09M
FLNA
14
Filana Therapeutics
FLNA
$46.4M
$5.21M 1.01%
+336,761
New +$7.12M
AVNR
15
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$4.63M 0.9%
+1,006,053
New +$3.46M
PTN
16
Palatin Technologies
PTN
$13.9M
$3.12M 0.61%
+4,160
New +$3.19M
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$378M
$2.72M 0.53%
+153,500
New +$2.99M
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
$2.61M 0.51%
+2,220
New +$2.11M
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.07M 0.4%
+69,953
New +$2.61M
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
$931K 0.18%
+151,406
New +$782K
PRTK
21
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$453K 0.09%
+12,500
New +$536K
GNVC
22
DELISTED
GenVec, Inc.
GNVC
$180K 0.03%
+48,610
New +$410K

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for BVF Inc, which disclosed 24 positions worth $515M. Its ten largest holdings account for 88% of the portfolio.

Its largest position is Ligand Pharmaceuticals: 5,805,529 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets.

  • BVF Inc's largest Q2 2013 buy was Ligand Pharmaceuticals: 5,805,529 shares worth $136M.
  • BVF Inc's ten largest holdings make up 88% of its $515M portfolio in Q2 2013.
  • BVF Inc disclosed 24 positions in Q2 2013, its first 13F filing on record.

Based on BVF Inc's 13F filing for Q2 2013, filed 14 Aug 2013.